Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis

被引：0

作者：

Krueger, J. G. ^{[1
]}

Garcet, S. ^{[1
]}

Cheng, J. ^{[2
]}

Kumar, S. ^{[3
]}

Tang, J. ^{[3
]}

Blau, J. ^{[2
]}

Zhao, Y. ^{[2
]}

Zhang, W. ^{[2
]}

Saha, B. ^{[2
]}

Arunachalam, V. ^{[3
]}

Heap, G. A. ^{[2
]}

Thakker, P. ^{[2
]}

Choudhury, A. ^{[2
]}

机构：

[1] Rockefeller Univ, Lab Invest Dermatol, New York, NY USA

[2] Takeda Pharmaceut Int Co, Gastrointestinal & Inflammat Therapeut Unit, Cambridge, MA USA

[3] Takeda Pharmaceut Int Co, Gastrointestinal & Inflammat Therapeut Unit, San Diego, CA USA

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2024年 / 144卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

265

引用

页码：S46 / S46

页数：1

共 50 条

[41] Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
Catlett, Ian M.
Gao, Lu
Hu, Yanhua
Banerjee, Subhashis
Krueger, James G.
DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2827 - 2839
[42] Evaluating the influence of baseline disease characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a phase 2 trial
Gordon, Kenneth
Papp, Kim
Gooderham, Melinda
Thaci, Diamant
Foley, Peter
Banerjee, Subhashis
Kundu, Sudeep
Kisa, Renata
Napoli, Andrew
Morita, Akimichi
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB59 - AB59
[43] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate/severe plaque psoriasis: onset of action in the phase 3 POETYK PSO-1 and PSO-2 trials
Foley, Peter
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 65 - 65
[44] EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
Armstrong, A.
Gooderham, M.
Warren, R. B.
Papp, K.
Strober, B.
Thaci, D.
Colston, E.
Throup, J.
Kundu, S.
Banerjee, S.
Blauvelt, A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 795 - 796
[45] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials
Armstrong, April W.
Warren, Richard B.
Sofen, Howard
Spelman, Lynda
Leonardi, Craig
Banerjee, Subhashis
Wang, Tao
Throup, John
Colston, Elizabeth
Napoli, Andrew
Kimball, Alexa B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB156 - AB156
[46] Evaluating influence of baseline characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a Phase 2 trial
Gordon, K.
Papp, K.
Gooderham, M.
Thaci, D.
Foley, P.
Morita, A.
Kundu, S.
Kisa, R.
Napoli, A.
Banerjee, S.
EXPERIMENTAL DERMATOLOGY, 2018, 27 : 29 - 30
[47] Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Achievement of Absolute PASI Thresholds in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Thaci, Diamant
Lebwohl, Mark
Gooderham, Melinda
Warren, Richard B.
Foley, Peter
Gottlieb, Alice B.
Banerjee, Subhashis
Hippeli, Lauren
Kisa, Renata
Griffiths, Christopher
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 119 - 120
[48] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials
Lebwohl, Mark
Gooderham, Melinda
Warren, Richard B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41
[49] DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
Arriens, C.
Askanase, A.
Furie, R.
Morand, E. F.
Van Vollenhoven, R.
Connors, K.
Davey, M.
Delev, N.
Shah, V.
Stevens, A.
Wegman, T.
Hobar, C.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1463 - 1463
[50] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials
Spelman, Lynda
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 66 - 66

← 1 2 3 4 5 →